A camera combined with AI could help further diagnosis of movement disorders in newborns

by Imen Trabelsi, François Jouen, Jean Bergounioux, The Conversation

edited by Sadie Harley, reviewed by Robert Egan

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Robert Egan

Senior Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

written by researcher(s)

proofread

The GIST Add as preferred source

Detecting impaired motor function as early as possible after birth with the help of a standard camera linked to intelligent systems can help diagnose infantile conditions characterized by hypotonia: reduced muscle tone, which can limit active movement. A research team is investigating this approach based on work carried out on babies with spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder.

In 2019, the drug Zolgensma made headline news as the world's most expensive treatment. The price of this medicine for spinal muscular atrophy (SMA) has been set at nearly 2 million euros per injection.

At the same time, what an extraordinary breakthrough! It promises to provide a definitive cure for a genetic disease that leads to extremely severe disabilities in children who survive what is the world's first hereditary peripheral neurological disorder.

Behind these staggering figures lies an urgent medical situation. For these therapies to be effective, it is essential to identify the condition as early as possible. This is precisely the challenge our team set out to tackle by using an ordinary camera coupled with artificial intelligence.

The aim was clear from the outset. Delays drastically reduce the effectiveness of the treatment. While the treatment can prevent neurons from dying, it cannot bring them back to life. Any delay in diagnosis—and, consequently, in starting treatment—represents an unacceptable loss of opportunity for patients.

What is spinal muscular atrophy?

SMA is a rare genetic condition that causes the progressive degeneration of the motor neurons that control muscle function.

In its most severe form—known as type 1 spinal muscular atrophy—infants with the condition rapidly lose the ability to move, sit up and eventually breathe. Without treatment, life expectancy rarely exceeds two years. In France, there is one case in every 6,000 to 10,000 births.

Since the introduction of new treatments, the prognosis has changed dramatically for children treated at a very early stage. Spinal muscular atrophy has, in fact, been included in routine neonatal screening in France since 2025. Not all countries have this screening in place yet. And even where it does exist, a complementary tool for rapid clinical assessment remains highly useful.

Hypotonia refers to reduced muscle tone, which can be accompanied by a reduction in, or even the complete absence of, active movements. This symptom is nonspecific and can be associated with many other childhood conditions, but it remains the first indicator that can prompt a diagnosis.

The challenge with clinical diagnosis

Before genetic testing, diagnosis relies on clinical observation. A specialist examines the newborn's muscle tone and reflexes. The term "hypotonic infant" is often used: the baby appears limp, and their limbs droop without resistance.

However, this assessment is subjective, varying from one practitioner to another, and is all too often made at a very late stage, by which time the symptoms have already progressed significantly.

This, then, is the real challenge: The therapeutic window is narrow.

Our approach: Motion capture

Our study involved 25 infants hospitalized in pediatric intensive care units: five cases with genetically confirmed SMA and 20 patients with normal neurological results. We used computer vision to analyze infants' spontaneous movements. The principle is simple: the infant is placed on a plain background, while a conventional camera captures its movements for 60 seconds; an artificial intelligence algorithm then analyzes the video footage frame by frame.

In practical terms, this study is based on a three-step video analysis pipeline.

The system first reconstructs a "digital skeleton" of the infant based on 12 anatomical joints, eight limb segments and four movement angles (pose estimations), using a real-time human pose estimation method called AlphaPose.

From this animated skeleton, hundreds of parameters are calculated (amplitude of gestures, movement limitations (depth), symmetry, frequency …). A total of 108 features were extracted. We then trained a supervised learning algorithm (XGBoost) capable of distinguishing typical motor skills from "altered" motor skills characteristic of spinal muscular atrophy.

Promising results

The results are encouraging: The algorithm correctly classified both groups with an accuracy of 97%.

Among the parameters that best distinguish the groups is the depth of movements, or movement limitation—in other words, the ability of the infant to move its limbs in space.

Babies with SMA show a significant difference in depth-axis motor motion, with detection sensitivity greater than 97%. The tool we developed rigorously measures this, turning a visual impression into objective data. What the clinician's eye intuitively perceives, the algorithm quantifies with precision.

To make the AI output understandable and thus incorporate it into clinical practice, we used a mathematical method called Shapley Additive Explanations (SHAP), which allows you to view the parameters that have been most influential in each algorithm decision.

A tool for other diseases causing hypotonia in infants

Our study was conducted before 2025, at a time when no systematic screening existed in France. Since then, SMA has been integrated into France's national newborn screening program, which retrospectively confirms the urgency behind our study.

But beyond SMA, many other diseases cause hypotonia in infants without any rapid assessment tool. Our work continues in this direction. While this tool does not set out to replace doctors, in a few minutes it gives practitioners an initial objective indicator to guide their diagnosis without specialized equipment.

Artificial intelligence does not perform miracles, but it makes visible what is invisible to the naked eye. When each week counts for an infant, AI's contribution to diagnosis becomes valuable.

Journal information: JAMA Pediatrics

Key medical concepts

Spinal Muscular AtrophyMotor impairment

Clinical categories

PediatricsChildren's healthNeurology Provided by The Conversation Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Citation: A camera combined with AI could help further diagnosis of movement disorders in newborns (2026, October 6) retrieved 6 October 2026 from https://medicalxpress.com/news/2026-10-camera-combined-ai-diagnosis-movement.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.